Considered for Treatment of patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
PBAC outcome
—
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
2
first 2024
Submissions
2
2024 → 2025
Eligible population
Adults with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Therapy area
Haematology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
ORR
Key trials
MagnetisMM-3, ENDEAVOR, MM-003, STORM
Comparator
Standard of care (carfilzomib + dexamethasone 51.0%, pomalidomide + dexamethasone 46.5%, selinexor + dexamethasone 2.5%)
Economic model
CUA
ICER note
ICER value(s) not disclosed in the public summary document; the document states the base case ICER 'remained high' but does not provide numeric values
Submission history
Jul 2024: Recommended with restriction · Authority Required